Skip to main content
. 2021 Feb 13;14(2):155. doi: 10.3390/ph14020155

Table 1.

In vitro activity of compounds 1a,b6a,b.

Structure Series A
R = m-CNPh
Series B
R = p-NO2Ph
%RA * IC50 ** (µM) %RA * IC50 ** (µM)
graphic file with name pharmaceuticals-14-00155-i001.jpg I II
3.1 ± 1.0 6.3 ± 0.9 18.2 ± 5.1 7.6 ± 1.6
graphic file with name pharmaceuticals-14-00155-i002.jpg 1a 1b
23.7 ± 5.0 35.5 ± 1.9 22.5 ±10.8 18.6 ± 1.7
graphic file with name pharmaceuticals-14-00155-i003.jpg 2a 2b
24.8 ± 1.8 41.9 ± 7.3 32.8 ± 2.3 -
graphic file with name pharmaceuticals-14-00155-i004.jpg 3a 3b
38.0 ± 7.6 - 23.0 ± 7.8 21.1 ± 2.7
graphic file with name pharmaceuticals-14-00155-i005.jpg 4a 4b
21.2 ± 1.0 39.3 ± 3.0 18.2 ± 4.9 27.5 ± 2.3
graphic file with name pharmaceuticals-14-00155-i006.jpg 5a 5b
75.0 ± 9.8 - 59.0 ± 4.3 -
graphic file with name pharmaceuticals-14-00155-i007.jpg 6a 6b
67.9 ± 6.6 - 32.7 ± 7.8 -

* % residual enzymatic activity at 100 µM; ** only for compounds with %RA ≤ 25%.